Associate Health Minister David Seymour warns Pharmac to modernise or risk falling behind
RNZ
The Associate Health Minister says Pharmac must modernise, "or it will fall behind."
David Seymour has told the agency to "innovate and optimise" to increase access to medicines and continue the "positive culture shift" that's been underway, such as exploring ways to "utilise AI".
Seymour released his latest letter of expectations today, with the hope of building on his letter from last year where he told the agency it was
inappropriate to keep considering the Treaty of Waitangi's place
in the health sector.
Since that letter of expectation, Seymour said the drug-buying agency has improved overall consultation and changed funding criteria based on public feedback.
The agency had also appointed a new chief executive to "cement positive change, and continue to move towards a more transparent, inclusive, and people-focused organisation."
"This is a good start. My letter of expectations for this year makes it very clear that there is still more work to be done. I expect this positive culture shift to continue," Seymour said.
Now, Seymour wanted Pharmac to modernise and "adopt faster, smarter processes and explore the use of AI to lift performance."
His expectations included:
Seymour told the agency he wanted it to report back to him by December this year on work done to consider the broader fiscal impacts to government and regarding societal and non-health outcomes of funding medicines and medical devices.
He also expected Pharmac to "renew its organisational culture and sharpen its strategic focus, ensuring it plays a more visible and constructive role across the wider health system."
As part of the "continuous improvement of organisational culture", Seymour said Pharmac needed to carry on giving effect to the Cabinet Circular specifying "Needs-based Service Provision" to meet the government's expectations for how the "targeting, commissioning and design of public services should be based on the needs of all New Zealanders."
Seymour said he's committed to ensuring the regulatory system for pharmaceuticals was not "unreasonably holding back access".
Sign up for Ngā Pitopito Kōrero
,
a daily newsletter curated by our editors and delivered straight to your inbox every weekday.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Techday NZ
4 hours ago
- Techday NZ
Healthcare leaders optimistic on GenAI, but face major hurdles
New research from NTT Data has revealed a significant gap between healthcare leaders' ambitions for generative artificial intelligence (GenAI) and their ability to deliver on these strategies. The findings, based on a survey of 425 healthcare decision-makers across 33 countries, indicate that while more than 80% of healthcare organisation leaders report having a well-defined GenAI strategy, only 40% believe that strategy is strongly aligned with their broader business objectives. Additionally, just 54% said their GenAI capability could be classified as high performing. Key challenges identified The research comes at a time when the UK Government's 10-year Health Plan has set a target to make the NHS the most AI-enabled health system in the world. While leaders in the sector widely recognise the potential for GenAI to accelerate research and development (94%) and improve patient outcomes, they also highlight a series of barriers, including a lack of necessary skills (75%), legacy infrastructure (91%), and security concerns (91%). A substantial majority (95%) of respondents consider cloud-based solutions as the most practical and cost-effective means for fulfilling their GenAI technology requirements. However, progress has been slowed by data security, privacy, ethical issues, and the challenges of regulatory compliance, according to the NTT Data report titled GenAI: The Care Plan for Powering Positive Health Outcomes . Tom Winstanley, Chief Technology Officer at NTT Data UK & Ireland, said: "Our report analyses the importance of AI to healthcare, which has just been demonstrated in the contents of the UK Government's latest 10 Year Health Plan for England. The plan aims to make the NHS the most AI-enabled health system in the world and calls for all hospitals to be fully adopt AI, driving the UK to the forefront of investment and adoption. To achieve this, it aims to support all doctors, nurses and healthcare professionals with trusted AI assistants, signalling a bridge across the skills gap exposed in the report, whilst securely leveraging the wealth of health data within the NHS." Security and compliance concerns Despite investment in GenAI showing benefits in compliance and adherence to processes, 91% of healthcare executives expressed concerns about privacy violations and the potential misuse of Protected Health Information (PHI). Only 42% strongly agreed that their current cybersecurity controls are effective in protecting GenAI applications. Nonetheless, the perceived benefits of GenAI remain high, with 87% of respondents agreeing that the long-term potential of GenAI outweighs the risks associated with security and legal challenges. Looking ahead, 59% plan to make significant investments in GenAI over the next two years. Technical and workforce readiness Outdated technology and insufficient data readiness also impact GenAI deployment. According to the research, 91% of respondents said that legacy infrastructure affects their ability to effectively use GenAI. Meanwhile, only 44% strongly agreed they had made sufficient investments in data storage and processing capabilities for GenAI workloads, and 48% had assessed the readiness of their data and platforms for such applications. Developments in patient care Human-focused GenAI solutions are seen as facilitating greater efficiency for clinical and administrative staff, while maintaining patient-centred care. Examples include using AI to predict chronic disease for early intervention and speeding up administrative checks. The report highlights NTT Data's collaborative work with The Royal Marsden, a cancer treatment centre in the UK, to develop an AI-powered radiology analysis service intended to support medical imaging research and improve outcomes for cancer patients. Flann Horgan, Vice President, Healthcare at NTT Data UK & I, said: "This partnership illustrates how AI technology can be harnessed for good. The ethical and secure use of AI in healthcare is central to our mission to build a smarter, healthier society, and this project is a blueprint for what responsible innovation looks like in practice. We are proud to support The Royal Marsden in pushing the boundaries of cancer research." Addressing the steps needed for success, Sundar Srinivasan, Senior Vice President, Healthcare, NTT Data North America, emphasised: "To achieve GenAI's full potential in healthcare, organisations must align the technology to their business strategies, develop comprehensive workforce training, and implement multi-layered governance strategies that prioritise people and keep humans in the loop. It's vital to transparently show how the technology benefits patients by complementing human workers." Survey methodology The report's respondents comprise 81% from large enterprises with more than 10,000 employees; 70% are from the C-suite, while 28% are vice presidents, heads or directors, and 3% are senior managers or specialists. A total of 28% hold IT-specific roles.
RNZ News
19 hours ago
- RNZ News
Risks identified with Gumboot Friday's 'fee-for-service' model
Mental Health Minister Matt Doocey says the programme is meeting expectations. Photo: RNZ / Samuel Rillstone Gumboot Friday's youth counselling initiative has had its $6m annual contract renewed , despite health officials identifying ongoing risks that practitioners could bill for services of poor quality or not delivered. Mental Health Minister Matt Doocey said the programme was meeting expectations, with more than 10,000 young people receiving free counselling in its first year, and the government was "backing Gumboot Friday to deliver more". A partially-redacted briefing to the Minister dated 30 May, released by the Health Ministry on Wednesday - along with [ other documents - noted "ongoing risk through this arrangement that practitioners invoice I Am Hope for services and do not deliver them". Some sections of the document were blanked out, citing the need to preserve "confidentiality of advice tendered by Ministers and officials". The briefing - which recommended the contract be renewed with some changes - noted the risk of non-delivery was no different to other "fee for service" arrangements. It said the charity had "significantly improved and streamlined some of its processes since the contract was developed". These included spot checking, auditing, client surveys and an electronic system to pick up "any unusual invoicing". "To date, I Am Hope [the parent charity of Gumboot Friday] has identified two practitioners that have departed from the agreed procedures and has removed them from the platform." In total there were more than 700 qualified counsellors registered on the platform. In the same section, entitled "Delivery Risks", Health Ministry officials wrote there was also a risk that Gumboot Friday's practitioners could "act unprofessionally" or fail to deliver quality service. A Ministry of Health weekly report said I Am Hope had "enhanced" its vetting process to include mandatory police checks for all practitioners registered before October 2024, and updated its Practitioner (Policies) Handbook in March. The charity now used CV Checker to speed up its verification process, but had limited ability to "scrutinise practice" since client and practitioner sessions had to remain private and confidential. All practitioners were members of professional associations, and the Ministry had not been advised of any complaints to date. Gumboot Friday and I Am Hope were working on evaluations of service delivery and the experiences of young people, while the Ministry was preparing an evaluation framework. In a preface to the documents, the Health Ministry said demographic information from I Am Hope's platform may have produced "potential double counting" of clients, as individuals reappeared across months. "It nevertheless provides additional information about the groups that are engaged in Gumboot Friday." The 30 May briefing said the Gumboot Friday service was "operationally different" to the original design. It recommended some changes to the contract, including increasing the number of sessions and clients, and removing some performance measures "which divert resources and create barriers to maximum performance". The officials advocated for scrapping the monthly limit of $500,000 (to allow for higher demand in some months) and current measures of reporting on wait times, which were not being consistently recorded as some young people contacted counsellors directly rather than going through the website. The original contract required Gumboot Friday to ensure most people could receive services "within 24 to 48 hours of seeking support with 3 to 5 days as a maximum wait time for the first meeting with the person" and provide monthly reporting of wait times. The latest report showed the average wait time for young people across January and February this year was 9.04 days, with 186 young people waiting more than five days. That was up from 5.78 days in November and December. "This increase was in part due to the holiday period in January 2025, however, the longer wait times persisted into February. I Am Hope has highlighted to practitioners the importance of responding promptly to service requests." The briefing also suggested the government could consider funding emergency and crisis referrals, and providing more cash to support evaluation and "verification activities".
Scoop
a day ago
- Scoop
Guidelines Released For Prescribing Psilocybin
Associate Minister of Health Associate Health Minister David Seymour is welcoming steps to provide medical practitioners with more tools to treat people with depression, with Medsafe publishing guidelines for experts wanting to prescribe Psilocybin. 'This is huge for people with depression who've tried everything else and are still suffering. If a doctor believes psilocybin can help, they should have the opportunity to do what's best for their patient,' says Mr Seymour. 'Recent changes have put New Zealand's settings in line with Australia, where authorised prescribers have been using psilocybin in clinical settings for some time. 'Psilocybin remains an unapproved medicine, but one highly experienced psychiatrist has already been granted authority to prescribe it to patients with treatment-resistant depression. 'This is excellent news for their patients, but there are other Kiwis in need in different parts of New Zealand who might have an appropriate practitioner nearby. 'Practitioners must meet a series of requirements to gain approval, including being registered with the Medical Council with a current practicing certificate, a good understanding and experience of the medicines and the psychotherapeutic processes involved in psychedelic-assisted therapy, and a detailed proposal of how they will administer the treatment that has been peer reviewed and will be considered by Medsafe. 'Soon more practitioners will have the ability to use this medicine, meaning more patients will benefit.'
